All In Biotech

NDA 218698 · Xtm Consulting

Lopressor

Metoprolol Tartrate · Oral

Last checked: Nov 19, 2026Latest source record: Jun 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2025

Aug 28, 2025

Approved uses

1

Original approval plus efficacy supplements

Registered trials

302

56 Phase 3, 19 recruiting

FAERS reports

86,471

59,888 serious, 9,924 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 29, 2026.

1. INDICATIONS AND USAGE Metoprolol Tartrate Tablets is a beta-adrenergic blocker indicated in the treatment of hemodynamically stable adult patients with myocardial infarction, to reduce the risk of cardiovascular mortality. ( 1.1 ) 1.1 Myocardial Infarction Metoprolol Tartrate Tablets is indicated in the treatment of hemodynamically stable adult patients with myocardial infarction (MI) to reduce cardiovascular mortality.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 28, 2025 Original approval · Type 5 - New Formulation or New Manufacturer LetterLetterLabel
1 products under this application
  • LOPRESSOR · METOPROLOL TARTRATE 12.5MG · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Metoprolol" as an intervention, any sponsor and status, largest first.

All 302 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • fatigue5,878
  • nausea5,108
  • dyspnoea5,035
  • diarrhoea5,014
  • dizziness3,953
  • death3,874
  • drug ineffective3,796
  • pain3,713
  • asthenia3,684
  • headache3,255
  • fall3,119
  • myocardial infarction3,041

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041,399
20051,811
20062,035
20071,422
20083,265
20092,706
20103,627
20115,835
20125,503
20132,009
20143,994
20154,233
20165,398
20175,594
20185,556
20195,428
20204,735
20213,713
20223,691
20233,488
20243,430
20254,141
20263,456

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Lopressor (Metoprolol Tartrate)

2024 spending

$310K

Beneficiaries

257

901 claims

Per beneficiary

$1,204

$2.67 per unit

View as table
YearSpending
2020$518,195
2021$487,155
2022$459,116
2023$369,969
2024$309,517

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,994 on PubMed

Sponsor: Xtm Consulting

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.